Biora Therapeutics, Inc. (BIORQ)
OTCMKTS · Delayed Price · Currency is USD
0.1350
-0.0650 (-32.50%)
Jul 29, 2025, 4:00 PM EDT
Biora Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2019 |
| 0.89 | 0 | 0.31 | 1.25 | 0.16 | 143.99 | Upgrade | |
Revenue Growth (YoY) | 4855.56% | -98.69% | -75.54% | 669.75% | -99.89% | 12.51% | Upgrade |
Cost of Revenue | - | - | - | - | - | 100.49 | Upgrade |
Gross Profit | 0.89 | 0 | 0.31 | 1.25 | 0.16 | 43.49 | Upgrade |
Selling, General & Admin | 35.33 | 37.31 | 38.04 | 73.3 | 60.04 | 120.21 | Upgrade |
Research & Development | 26.44 | 29.84 | 24.05 | 45.79 | 47.74 | 63.4 | Upgrade |
Operating Expenses | 61.77 | 67.15 | 62.09 | 119.08 | 107.78 | 183.61 | Upgrade |
Operating Income | -60.87 | -67.14 | -61.78 | -117.84 | -107.62 | -140.12 | Upgrade |
Interest Expense | -7.32 | -9.82 | -10.99 | -12.64 | -9.92 | -9.2 | Upgrade |
Interest & Investment Income | - | - | - | - | - | 0.58 | Upgrade |
Other Non Operating Income (Expenses) | 52.73 | 15.21 | 21.6 | -47.27 | -13.88 | - | Upgrade |
EBT Excluding Unusual Items | -15.47 | -61.75 | -51.17 | -177.74 | -131.42 | -148.74 | Upgrade |
Gain (Loss) on Sale of Investments | -56.2 | -56.2 | 5.73 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.01 | -0.02 | -0.54 | - | - | - | Upgrade |
Asset Writedown | - | -0.1 | -0.55 | - | - | - | Upgrade |
Other Unusual Items | 35.95 | -6.36 | -2.72 | -0.9 | -11.2 | - | Upgrade |
Pretax Income | -35.73 | -124.42 | -49.25 | -178.64 | -142.62 | -148.74 | Upgrade |
Income Tax Expense | -0.16 | -0.09 | -0.42 | -0.12 | -37.53 | -0.71 | Upgrade |
Earnings From Continuing Operations | -35.57 | -124.33 | -48.83 | -178.52 | -105.09 | -148.04 | Upgrade |
Earnings From Discontinued Operations | 4.04 | 0.22 | 10.67 | -68.89 | -87.44 | - | Upgrade |
Net Income | -31.54 | -124.12 | -38.16 | -247.41 | -192.53 | -148.04 | Upgrade |
Preferred Dividends & Other Adjustments | - | - | - | - | 0.27 | 80.79 | Upgrade |
Net Income to Common | -31.54 | -124.12 | -38.16 | -247.41 | -192.8 | -228.83 | Upgrade |
Shares Outstanding (Basic) | 3 | 2 | 1 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 3 | 2 | 1 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | 159.11% | 106.59% | 98.51% | 249.49% | 463.47% | 4.84% | Upgrade |
EPS (Basic) | -10.46 | -78.69 | -49.98 | -643.27 | -1751.86 | -11716.09 | Upgrade |
EPS (Diluted) | -10.46 | -78.69 | -49.98 | -643.27 | -1751.86 | -11716.09 | Upgrade |
Free Cash Flow | -46.2 | -48.6 | -65.21 | -168.34 | -169.62 | -109.85 | Upgrade |
Free Cash Flow Per Share | -15.33 | -30.81 | -85.41 | -437.68 | -1541.23 | -5624.34 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 30.21% | Upgrade |
Operating Margin | -6824.33% | -1678575.00% | -20256.07% | -9449.64% | -66431.48% | -97.31% | Upgrade |
Profit Margin | -3535.76% | -3102875.00% | -12510.49% | -19840.58% | -119009.88% | -158.92% | Upgrade |
Free Cash Flow Margin | -5179.71% | -1215050.00% | -21380.00% | -13499.68% | -104700.62% | -76.29% | Upgrade |
EBITDA | -60.43 | -66.59 | -60.87 | -116.4 | -106.18 | -135.44 | Upgrade |
EBITDA Margin | - | - | - | - | - | -94.06% | Upgrade |
D&A For EBITDA | 0.44 | 0.56 | 0.91 | 1.44 | 1.44 | 4.68 | Upgrade |
EBIT | -60.87 | -67.14 | -61.78 | -117.84 | -107.62 | -140.12 | Upgrade |
EBIT Margin | - | - | - | - | - | -97.31% | Upgrade |
Advertising Expenses | - | - | - | - | - | 2.2 | Upgrade |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.